1. Home
  2. WPP vs ADPT Comparison

WPP vs ADPT Comparison

Compare WPP & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WPP plc

WPP

WPP plc

N/A

Current Price

$24.75

Market Cap

4.0B

ML Signal

N/A

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

N/A

Current Price

$24.13

Market Cap

4.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WPP
ADPT
Founded
1985
2009
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0B
4.1B
IPO Year
1996
2019

Fundamental Metrics

Financial Performance
Metric
WPP
ADPT
Price
$24.75
$24.13
Analyst Decision
Hold
Strong Buy
Analyst Count
2
9
Target Price
N/A
$17.78
AVG Volume (30 Days)
296.1K
1.6M
Earning Date
03-19-2026
05-05-2026
Dividend Yield
11.68%
N/A
EPS Growth
N/A
63.89
EPS
N/A
N/A
Revenue
N/A
$276,976,000.00
Revenue This Year
N/A
$3.98
Revenue Next Year
$4.32
$22.72
P/E Ratio
$38.96
N/A
Revenue Growth
N/A
54.77
52 Week Low
$14.81
$12.00
52 Week High
$27.78
$26.87

Technical Indicators

Market Signals
Indicator
WPP
ADPT
Relative Strength Index (RSI) 51.17 47.15
Support Level $23.97 $23.92
Resistance Level $27.67 $26.51
Average True Range (ATR) 0.57 1.01
MACD -0.39 -0.29
Stochastic Oscillator 24.48 17.66

Price Performance

Historical Comparison
WPP
ADPT

About WPP WPP plc

Headquartered in the United Kingdom, WPP is the world's largest ad holding company based on annual revenue. Its services, which include traditional and digital advertising, public relations, and consulting, are provided worldwide, with over 70% of its revenue coming from more developed regions such as North America, the UK, and Western Europe. WPP is the largest media buying entity in the world.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: